Lipopeptide antibiotics for XDR Gram-negative infections

脂肽抗生素治疗 XDR 革兰氏阴性菌感染

• 批准号: nhmrc : 1139609
• 负责人: Dr Mark Blaskovich
• 金额: $ 67.27万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Development Grants
• 财政年份: 2018
• 资助国家: 澳大利亚
• 起止时间: 2018-01-01 至 2020-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/lipopeptide-antibiotics-xdr-negative-infections/1319035
• 关键词: Lipopeptide; antibiotics; XDR; Gram; negative

The polymyxins are a drug class considered to be a last-resort treatment option for multidrug-resistant (MDR) and extremely drug resistant (XDR) Gram-negative infections. Unfortunately resistance is rapidly developing against these antibiotics, leaving no effective therapies and resulting in patient death. This project aims to develop an antibiotic with superior spectra of action and improved safety profiles compared to the polymyxins, with activity against polymyxin-resistant bacteria.

多粘菌素类药物被认为是多重耐药（MDR）和极端耐药（XDR）革兰氏阴性菌感染的最后治疗选择。不幸的是，对这些抗生素的耐药性正在迅速发展，没有有效的治疗方法，并导致患者死亡。该项目旨在开发一种与多粘菌素相比具有上级作用谱和改善的安全性特征的抗生素，其对多粘菌素耐药细菌具有活性。